Acta Scientific Ophthalmology (ISSN: 2582-3191)

Research Article Volume 5 Issue 2

A Plethora of Actions of Curcumin - A Magical Agent for Treatment of Wide Range of Diseases Varying from Neuroinflammatory Disease (AD, PD)-IBD to DM and CVD, NAFLD, NASH Along with Various Cancers - A Systematic Review

Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3

1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda - A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: November 22, 2021; Published: January 17, 2022


Curcumin represents a yellow polyphenolic pigment derived from the plant Curcuma longa (turmeric) rhizome that has been put in utilization over centuries for cuisine art besides coloring of foods, as a constituent of separate medicinal formulations that has been used over and over in Ayurveda along with Chinese medicine. In the current decades it has been exhaustively evaluated for its biological actions. Thus here we conducted a systematic review with the utilization of search engines like pubmed, google scholar, web of science, Cochrane library from 1900 till date with the utilization of MeSH terms Curcumin; Neuroinflammation; Alzheimer’s disease (AD); parkinson’s disease (PD); antioxidant actions; other anti-inflammatory actions; cardio protection; hepatoprotection in liver fibrosia; non alcoholic fatty liver disease (NAFLD); non alcoholic steatohepatitis (NASH); Anti cancer actions. We observed a total of over 3000 articles but selected only 53 articles for this review with the journals constraints of up to 50 references. No meta-analysis was done. Here we have reviewed in detail the mechanism of action of Curcumin in various above mentioned diseases along with transcription factors involved. Recently even in COVID its use has got documented. Although use in Alzheimer’s disease studied extensively human studies are still battling to get a concrete answer. In case of cancers, usually it is a good coagent with other chemotherapeutic drugs, might hamper human papilloma virus (HPV) infection as well as avoid cancer cervix generation. In case of NASH, or liver cirrhosis its use with beta blockers might aid in conversion back towards normalcy.

Keywords: Curcumin; Anti Inflammatory; Anti Oxidant; Neuro Shielding; Cardio Shielding; Hepatoprotection; Anti Cancer Actions


  1. Milobedzka J., et al. “Zur Kenntnis des Curcumins”. Berichte der deutschen chemischen Gesellschaft 43 (1910): 2163-2170.
  2. Sharifi -Rad., et al. “Turmeric and its major compound Curcumin on health: bioactive effects and safety profiles for food, Pharmaceutical, Biotechnological, and medicinal applications”. Frontiers in Pharmacology 11 (2020): 01021.
  3. Yeung AWK., et al. “Curcumin: Total scale analysis of the scientific literature”. Molecules 24 (2019): 1393.
  4. Xu XY., et al. “Bioactivity, health benefits, and related molecular mechanisms of Curcumin: current progress, challenges and perspectives”. Nutrients 10 (2018): 1553.
  5. Priyadarsini KL., et al. “Role of phenolic-O-Hand methylene hydrogen on the free radical reactions and antioxidant activity of curcumin”. Free Radical Biology and Medicine 35 (2003): 475-484.
  6. , et al. “Role of H-bond formation in the photo reactivity of curcumin”. Spectroscopy 22 (2008): 187-198.
  7. AK Tuba and GulcinI. “Anti-oxidant and radical scavenging properties of curcumin”. Chemico-Biological Interactions 174 (2008): 27-37.
  8. Dai W., et al. “Curcumin provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE signaling pathway”. Brain Research Bulletin 140 (2018): 65-71.
  9. Edwards RL., et al. “The anti-inflammatory activity of Curcumin is mediated by its Oxidative Metabolites”. Journal of Biological Chemistry 292 (2017): 21243-21252.
  10. Aggarwal BB and Sung B. “Pharmacological basis for the role of Curcumin in chronic disease: an age-old spice with modern targets”. Trends Pharmacology Science 30 (2009): 85-94.
  11. Yang H., et al. “Curcumin enhances anticancer effects of 5-fluorouracil against gastric cancer through down regulation of COX2 and NFκB signaling pathways”. Journal of Cancer 8 (2017): 3697-3706.
  12. Teter B., et al. “Curcumin restores innate immune, Alzheimer’s disease risk gene expression to ameliorate Alzheimer’s pathogenesis”. Neurobiology of Disease 127 (2019): 432-448.
  13. Salehi B., et al. “Curcumin’s nanomedicine formulations for therapeutic application in Neurological disease”. Journal of Clinical Medicine 2 (2020a): 430.
  14. Cianciulli A., et al. “PI3K/Akt signaling pathway plays a crucial role in the anti-inflammatory effects of Curcumin on LPS activated microglia”. International Immuno Pharmacology 36 (2016): 282-290.
  15. Chen N., et al. “Suppression of the TGF-beta/Smad signaling pathway and inhibition of hepatic stellate cells proliferation play a role in the hepatoprotective effects of Curcumin against alcohol induced hepatic fibrosis”. International Journal of Molecular Medicine 34 (2014): 1110-1116.
  16. Goozee KG., et al. “Examining the Potential Clinical value of Curcumin in the prevention and diagnosis of Alzheimer’s disease”. British Journal of Nutrition 115 (2016): 449-465.
  17. Ganesh P., et al. “A Potential role of periodontal inflammation in Alzheimer’s disease: A review”. Oral Health and Preventive Dentistry 15 (2017): 7-12.
  18. Qureshi M., et al. “Therapeutic Potential of Curcumin for multiple sclerosis”. Neurological Sciences 2 (2018): 207-214.
  19. Yance DRJR and Sagar SM. “Targeting angiogenesis with integrative cancer Therapies”. Integrative Cancer Therapies 5 (2006): 9-29.
  20. Astinfeshan M., et al. “Curcumin inhibits angiogenesis in endothelial cells using down regulation of the PI3K/Akt signaling pathway”. Food Bioscience 29 (2019): 86-93.
  21. Kandoth C., et al. “Mutational landscape and significance across 12 major cancer types”. Nature 502 (2013): 332-339.
  22. Hermeking H. “p53 enters the microRNA world”. Cancer Cell 12 (2007): 414-418.
  23. Ye M., et al. “Curcumin promotes apoptosis by activating the p53- miR 192-5p/215-XIAP pathway in non-small cells lung cancer”. Cancer Letters 357 (2015): 196-205.
  24. Watson JL., et al. “Curcumin causes super oxide anion production and p53- independent apoptosis in human colon cancer cells”. Cancer Letters 297 (2010): 1-8.
  25. Chiu TL and Su CC. “Curcumin inhibits proliferation and migration by increasing the Bax to Bcl2 ratio and decreasing nuclear factor κBp65 expression in breast cancer MDA MB231 cells”. International Journal of Molecular Medicine 23 (2009): 469-475.
  26. Cao Q., et al. “Ras/ERK signaling pathway is involved in Curcumin induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells”. Journal of Asian Natural Products Research 17 (2015): 56-63.
  27. Rana C., et al. “Downregulation of PI3K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by diclofenac and Curcumin in colon cancer”. Molecular and Cellular Biochemistry 402 (2017): 225-241.
  28. Kasi PD., et al. “Molecular targets of Curcumin for cancer therapy: an updated review”. Tumor Biology 37 (2016): 13017-13028.
  29. , et al. “Curcumin suppresses the colon cancer proliferation by inhibiting Wnt/β-catenin signaling pathway via miR130a”. Frontiers in Pharmacology 8 (2017): 877.
  30. Man S., et al. “Curcumin enhances the anti-cancer effects of Paris Saponin II in lung cancer cells”. cell proliferation 51 (2018): e12458.
  31. Marquardt JU., et al. “Curcumin effectively inhibits oncogenic nuclear factor Κappa B signaling and restrains stemness features in liver cancer”. Journal of Hepatology 63 (2015): 661-669.
  32. Shanmugan MK., et al. “The multifaceted role of curcumin in cancer prevention and treatment”. Molecules 20 (2015): 2728-2769.
  33. Rajitha B and Nagarajan GP. “Curcumin and genistein role in regulation of STAT3- in pancreatic cancer. In role of transcription factors in Gastrointestinal malignancies”. Eds GP Nagaraju, PV Bramhachari (Singapore: Springer Singapore) (2017): 427-435.
  34. Macias-Perez JR., et al. “Curcumin and α/β adrenergic antagonist co treatment reverses liver cirrhosis in hamsters: participation of Nrf2 and NFκB”. Journal of Immunology Research (2019): 3019794-3019794.
  35. Choudhary ST., et al. “Vesicular (liposomal and nanoparticulated) delivery of curcumin: a comparative study on carbon tetrachloride-mediated Oxidative Hepatocellular damage in rat model”. International Journal of Nanomedicine 11 (2016): 2179-2193.
  36. Lee HY., et al. “Turmeric extract and its active compound, curcumin, protect against chronic CCL4- induced liver damage by enhancing anti oxidation”. BMC Complementary and Alternative Medicine 16 (2016): 316.
  37. Farzaei MH., et al. “Curcumin in liver diseases: a systematic review of the cellular mechanisms of Oxidative stress and Clinical perspective”. Nutrients 7 (2018): 855.
  38. Badria FA., et al. “Curcumin attenuates iron accumulation and Oxidative stress in the liver and spleen of chronic iron overloaded rats”. PLoS One 10 (2015): e13456.
  39. Afrin R., et al. “Curcumin ameliorates streptozocin induced liver damage through modulation of endoplasmic reticulum stress mediated apoptosis in Diabetic rats”. Free Radical Research 49 (2015): 279-289.
  40. Granados-Castro LF., et al. “Curcumin prevents paracetamol induced liver mitochondrial alterations”. Journal of Pharmacy and Pharmacology 68 (2016): 245-256.
  41. Gou M., et al. “Curcumin loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo”. Nanoscale 3 (2011): 1558-1567.
  42. Zhong W., et al. “Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppression of Oxidative stress related inflammation via PI3K/AKT and NF-Κappa B- related signaling”. Biomedicine and Pharmacotherapy 83 (2016): 302-313.
  43. Zhang F., et al. “Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells”. Journal of Cellular and Molecular Medicine 18 (2014): 1392-1406.
  44. Li H., et al. “Curcumin, the golden spice for treating cardiovascular diseases”. Biotechnology Advances 38 (2019): 107343.
  45. Salehi B., et al. “Therapeutic applications of Curcumin’s nanomedicine formulations in cardiovascular diseases”. Journal of Clinical Medicine 9.3 (2020b): 746.
  46. Pittala V., et al. “Effects of polyphenolic derivatives in hemoxygenase system in metabolic dysfunction”. Current Medicinal Chemistry 25 (2018): 1577-1595.
  47. Sunagawa Y., et al. “Curcumin and its demothoxy derivatives possess p300HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes”. Journal of Pharmacological Sciences 136 (2018): 212-217.
  48. Monfoulet LE., et al. “Curcumin modulates endothelial permeability and monocyte trans endothelial migration by affecting endothelial cell dynamics”. Free Radical Biology and Medicine 112 (2017): 109-120.
  49. Yao Y., et al. “Curcumin exerts its antihypertensive effect by down regulating the AT1 receptor Vascular smooth muscle cells”. Scientific Reports 6 (2016): 25579.
  50. Cao O., et al. “Dickkopf3 upregulation mediates the cardioprotective effects of Curcumin on chronic heart failure”. Molecular Medicine Reports 17 (2018): 7249-7257.
  51. Subramani PA., et al. “Clinical trials of Curcumin, camptothecin, astaxanthine and biochanin”. Natural product-derived compounds in clinical trials 136 (2018): 212-217.
  52. Zhu LN., et al. “Curcumin Intervention for cognitive functions in different types of people: a systematic review and meta-analysis”. Phytotherapy Research 3 (2018): 524-533.
  53. Teymouri M., et al. “Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular molecular, and pre-Clinical features”. Bio Factors 43 (2017): 331-346.
  54. Kulvinder Kochar Kaur., et al. “Potential role of Epigenetic Modulation in prevention or therapy for Diabetic Kidney Disease-still a dream or a reality-A Systematic Review”. Diabetic Nephropathy and Diabetes Management 1:1 (2021): 1-26.
  55. Lim KM and Hadinoto K. “High payload buccal delivery system of amorphous curcumin- Chitosan Nanoparticle Complex in Hydroxypropyl Methylcellulose and Starch Films”. International Journal of Molecular Sciences 17 (2019): 9399.


Citation: Kulvinder Kochar Kaur., et al. “A Plethora of Actions of Curcumin - A Magical Agent for Treatment of Wide Range of Diseases Varying from Neuroinflammatory Disease (AD, PD)-IBD to DM and CVD, NAFLD, NASH Along with Various Cancers - A Systematic Review".Acta Scientific Ophthalmology 5.2 (2022): 09-19.


Copyright: © 2022 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US